BeOne Medicines shared on LinkedIn:
“News for Investors and Media:
Today, the U.S. FDA granted approval for our PD-1 inhibitor in combination with a HER2-targeting bispecific antibody plus chemotherapy for the first-line treatment of HER2+ unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA), regardless of PD-L1 status.
Despite advances in care, GEA continues to represent a substantial unmet need in the U.S., especially for the roughly one in five patients with HER2+ disease, which has historically been difficult to treat.
This approval is an important milestone for BeOne as we continue to expand the impact of our solid tumor portfolio for patients living with cancer.
You can also read: FDA Approves Ziihera With and Without Tislelizumab Plus Chemotherapy for First-Line HER2-Positive Gastroesophageal Adenocarcinoma
